2[1]Janice K B,Wanju S D,Gretchen S D,et al.The Art and Science of Risk Management[J].Drug Safety,2006,28(1):1-18.
3[2]Guideline for industry:EIA.The extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions[EB/OL].[2006-11-23].http://www.fda.gov/cdr/guidance/ichela.pdf.
4[3]Enclosure pdufa reauthorization performance goals and procedures[EB/OL].[2006-11-23].Http://www.fda.gov/oc/pdufa/PDUFAIII Goals.Html.
